September 1, 2010 - Wearable Defibrillator to be Showcased at Heart Failure Society of America 2010


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637



Device Provides Patients with Heart Failure Protection from Sudden Cardiac Arrest

September 1, 2010CHELMSFORD, MASS.– ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator in Booth 519 at the Heart Failure Society of America (HFSA) 14th Annual Scientific Meeting September 12-15 in San Diego.

Heart failure is estimated to afflict approximately 5 million Americans and is the only major cardiovascular disorder on the rise. It is estimated that 550,000 new cases of heart failure are diagnosed in the United States each year. In addition, it has been estimated that heart failure contributes to about 290,000 deaths per year.  Patients with heart failure are at high risk of sudden cardiac arrest (SCA), especially immediately following an acute event such as hospitalization for heart failure decompensation or myocardial infarction.  The risk of sudden cardiac death following a myocardial infarction is the highest in the first 30 days,  and patients with heart failure following a myocardial infarction are at 4-6 times greater risk. 

The LifeVest is worn by patients at risk of SCA, allowing their physicians time to assess their long-term arrhythmic risk and make appropriate plans.  The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients with SCA.

“The LifeVest is an emerging standard of care for newly diagnosed heart failure patients, especially those with a recent myocardial infarction,” said Richard A. Packer, Chief Executive Officer of ZOLL. “Medical therapy optimization and stabilization can take up to three months or more. The LifeVest can protect these patients from SCA during this high-risk period while their hearts recover.”

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk. 

To date, the LifeVest has been prescribed to more than 25,000 patients. For more information, go to or 1.800.543.3267.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly  Report on Form 10-Q filed with the SEC on May 14, 2010. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and  LifeVest are registered trademarks of ZOLL Medical Corporation.